FDA-Approved Baxdrostat Adds New Mechanism for Uncontrolled Hypertension

The FDA approval of baxdrostat (Baxfendy™, AstraZeneca) marks a notable development in hypertension management, introducing a first-in-class aldosterone synthase inhibitor for adults whose blood pressure remains inadequately controlled despite treatment with other antihypertensive medications.¹ In this interview with Patient Care Online, Payal Kohli, MD, a general and preventive cardiologist based in Denver, Colorado, discusses why the drug’s mechanism may be clinically meaningful for primary care physicians managing patients with persistent hypertension.

Unlike mineralocorticoid receptor antagonists, which block aldosterone activity after the hormone has already been produced, baxdrostat works upstream by inhibiting aldosterone synthase, the enzyme involved in aldosterone production. Kohli described this as a “parallel mechanism of action” to the thiazide diuretics, ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers commonly used in primary care. She also noted that baxdrostat may be particularly relevant for patients taking 2 or more antihypertensive medications who remain above goal.

Kohli reviewed the BaxHTN trial findings, including the approximately 9- to 10-mm Hg placebo-adjusted reduction in seated systolic blood pressure at 12 weeks.² Although BaxHTN was not an outcomes trial, she emphasized that this magnitude of reduction is clinically important given the established association between systolic blood pressure lowering and reduced cardiovascular risk.

The discussion also addresses how baxdrostat may fit into current treatment pathways, particularly for patients who are not controlled or cannot tolerate existing multidrug regimens. Kohli highlights key safety considerations for primary care clinicians, including checking kidney function before initiation and monitoring potassium, sodium, and renal function after starting therapy or adjusting other medications that affect potassium homeostasis. She also discusses the potential importance of 24-hour blood pressure control, given baxdrostat’s prolonged half-life and the prognostic significance of morning blood pressure elevations.

References:
1. Jennings S. FDA Approves Baxdrostat for Uncontrolled Hypertension on Background Therapy. Patient Care Online. May 18, 2026. https://www.patientcareonline.com/view/fda-approves-baxdrostat-for-uncontrolled-hypertension-on-background-therapy

2. Flack JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025. Aug 30:10.1056/NEJMoa2507109. doi:10.1056/NEJMoa2507109